Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of long QT syndrome
3.2.1.2 Technological advancements in treatment modalities
3.2.1.3 Advancement in genetic testing and diagnosis
3.2.1.4 Growing geriatric population
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of surgical procedures
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Million)
5.1 Key trends
5.2 Long QT syndrome type 1
5.3 Long QT syndrome type 2
5.4 Long QT syndrome type 3
5.5 Other types
Chapter 6 Market Estimates and Forecast, By Treatment, 2021 – 2032 ($ Million)
6.1 Key trends
6.2 Medication
6.2.1 By drug type
6.2.1.1 Potassium supplements
6.2.1.2 Beta-blockers
6.2.1.3 Sodium channel blockers
6.2.2 By distribution channel
6.2.2.1 Hospital pharmacies
6.2.2.2 Retail pharmacies
6.2.2.3 Online pharmacies
6.3 Surgical procedures
6.3.1 By procedure type
6.3.1.1 Implantable cardioverter-defibrillator (ICD) placement
6.3.1.2 Left cardiac sympathetic denervation (LCSD)
6.3.1.3 Cardiac transplantation
6.3.2 By end-use
6.3.2.1 Hospitals
6.3.2.2 Cardiac centers
6.3.2.3 Other end-users
Chapter 7 Market Estimates and Forecast, By Diagnosis 2021 – 2032 ($ Million)
7.1 Key trends
7.2 Tests
7.3 Electrocardiogram
7.4 Genetic testing
7.5 Other diagnosis types
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Abbott Laboratories
9.2 AstraZeneca
9.3 Bayer AG
9.4 Boehringer Ingelheim
9.5 Boston Scientific Corporation
9.6 Bristol Myers Squibb
9.7 GSK plc
9.8 Medtronic Plc
9.9 Merck & Co., Inc.
9.10 Pfizer Inc.
9.11 Sanofi
